胶质母细胞瘤放疗、淋巴细胞减少与宿主免疫能力
本文综述了放疗对胶质母细胞瘤(GBM)的免疫调节效应及其与淋巴细胞减少的关联,指出系统性淋巴细胞减少与不良肿瘤结局相关,放疗是导致淋巴细胞耗竭的重要原因,并讨论了脑损伤免疫抑制背景及其他影响因素,提出调整放疗策略以保留抗肿瘤免疫反应可能改善疗效。
要点
- 系统性淋巴细胞减少与GBM不良肿瘤结局相关。
- 放疗是导致淋巴细胞耗竭的重要可干预医源性因素。
- 调整放疗策略以保留免疫反应可能改善GBM疗效。
核心结论
- 放疗是显著且潜在可干预的医源性免疫抑制因素,可能限制GBM及其他肿瘤的治疗成功。
研究设计与样本
- 综述,描述放疗与淋巴细胞减少的关联及GBM免疫抑制背景。
主要发现
- 系统性淋巴细胞减少与不良肿瘤结局相关。
- 放疗是淋巴细胞耗竭的重要 contributing 原因。
- 肿瘤与脑损伤的系统性免疫背景参与免疫抑制。
- 合并用药和治疗等其他因素也 contribute 淋巴细胞减少。
临床怎么用
- 考虑调整放疗策略以更允许旺盛的抗肿瘤免疫反应,可能改善恶性肿瘤结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Radiotherapy is cytotoxic to tumor cells and is therefore a critical component of therapy for many malignancies, including glioblastoma (GBM). We now appreciate the value of the immunomodulatory effects of radiation that may be important to overall therapeutic success in some patients with this primary brain tumor. Although potentially beneficial immune-stimulating properties of radiotherapy treatment have been the focus of recent study, this modality is actually at the same time associated with the depletion of lymphocytes, which are crucial to the defense against neoplastic development and progression. In this review, we describe the association of systemic lymphopenia with poor tumor outcome, present evidence that radiotherapy is an important contributing cause of lymphodepletion, describe the systemic immune context of tumor and brain injury that contributes to immunosuppression, describe other contributing factors to lymphopenia including concomitant medications and treatments, and speculate about the role of the normal physiologic response to brain injury in the immunosuppressive dynamics of GBM. Radiotherapy is one significant and potentially actionable iatrogenic suppressor of immune response that may be limiting the success of therapy in GBM and other tumor types. Altered strategies for radiotherapy more permissive of a vigorous antineoplastic immune response may improve outcome for malignancy.
引用
- Kleinberg L, Sloan L, Grossman S, et al. Radiotherapy, Lymphopenia, and Host Immune Capacity in Glioblastoma: A Potentially Actionable Toxicity Associated With Reduced Efficacy of Radiotherapy. Neurosurgery. 2019. PMID: 31232425. doi:10.1093/neuros/nyz198
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。